Fampridine-SR Update - for the proposed indication of improvement of walking ability in people with multiple sclerosis (MS).

Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR

Company to Host Investor Conference Call on Thursday, October 15 at 8:00 a.m. HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 9, 2009-- Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Peripheral and Central Nervous System Drugs Advisory Committee meeting to review Acorda’s New Drug Application (NDA) for Fampridine-SR for the proposed indication of improvement of walking ability in people with multiple sclerosis (MS). The Prescription Drug User Fee Act (PDUFA) action date for the Fampridine-SR NDA is October 22, 2009. The Advisory Committee meeting is scheduled for 8:00 a.m. ET on Wednesday, October 14th. The briefing materials can be accessed at: http://www.fda.gov/AdvisoryCommittees/WhatsNew/default.htm Continue Reading this news release

============================================